DK3403657T3 - Anvendelse af oligouronater til behandling af slimhyperviskositet - Google Patents

Anvendelse af oligouronater til behandling af slimhyperviskositet Download PDF

Info

Publication number
DK3403657T3
DK3403657T3 DK18179968.5T DK18179968T DK3403657T3 DK 3403657 T3 DK3403657 T3 DK 3403657T3 DK 18179968 T DK18179968 T DK 18179968T DK 3403657 T3 DK3403657 T3 DK 3403657T3
Authority
DK
Denmark
Prior art keywords
hypervisicity
oligouronates
slim
treatment
slim hypervisicity
Prior art date
Application number
DK18179968.5T
Other languages
English (en)
Inventor
Kurt Ingar Draget
Olav Åsmund Smidsrød
Catherine Taylor
Original Assignee
Norwegian Univ Sci & Tech Ntnu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35429950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3403657(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Norwegian Univ Sci & Tech Ntnu filed Critical Norwegian Univ Sci & Tech Ntnu
Application granted granted Critical
Publication of DK3403657T3 publication Critical patent/DK3403657T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18179968.5T 2005-10-06 2006-10-06 Anvendelse af oligouronater til behandling af slimhyperviskositet DK3403657T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0520375A GB2430881B (en) 2005-10-06 2005-10-06 Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
EP10189506.8A EP2311497B1 (en) 2005-10-06 2006-10-06 Use of oligouronates

Publications (1)

Publication Number Publication Date
DK3403657T3 true DK3403657T3 (da) 2022-02-28

Family

ID=35429950

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10189506.8T DK2311497T3 (da) 2005-10-06 2006-10-06 Anvendelse af oligouronater
DK06794671.5T DK1942938T3 (da) 2005-10-06 2006-10-06 Anvendelse af oligouronater til behandling af slim-hyperviskositet
DK18179968.5T DK3403657T3 (da) 2005-10-06 2006-10-06 Anvendelse af oligouronater til behandling af slimhyperviskositet

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK10189506.8T DK2311497T3 (da) 2005-10-06 2006-10-06 Anvendelse af oligouronater
DK06794671.5T DK1942938T3 (da) 2005-10-06 2006-10-06 Anvendelse af oligouronater til behandling af slim-hyperviskositet

Country Status (14)

Country Link
US (2) US8673878B2 (da)
EP (4) EP3403657B1 (da)
JP (1) JP5313677B2 (da)
KR (1) KR101144576B1 (da)
CN (1) CN101325973B (da)
AU (1) AU2006298544B2 (da)
BR (1) BRPI0616982B8 (da)
CA (1) CA2624568C (da)
DK (3) DK2311497T3 (da)
EA (1) EA015436B1 (da)
ES (3) ES2688971T3 (da)
GB (1) GB2430881B (da)
PL (1) PL3403657T3 (da)
WO (2) WO2007039754A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2430881B (en) 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
GB0707096D0 (en) * 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
RU2527894C2 (ru) 2007-11-27 2014-09-10 Альгифарма ИПР АС Использование альгинатных олигомеров в борьбе с биопленками
GB0904941D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
GB0904942D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
RU2582938C2 (ru) 2009-06-03 2016-04-27 АльгиФарма АС Альгинатные олигомеры для применения в преодолении множественной лекарственной устойчивости у бактерий
GB0909529D0 (en) 2009-06-03 2009-07-15 Algipharma Ipr As Alginate oligomers for the inhibition of microbial adherence to surfaces
GB0909557D0 (en) 2009-06-03 2009-07-15 Algipharma Ipr As Anti-microbial alginate oligomers
GB201116010D0 (en) 2011-09-15 2011-10-26 Algipharma As Use of alginate oligomers to enhance the effects of antifungal agents
US9987235B2 (en) 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
GB201322777D0 (en) 2013-12-20 2014-02-05 Algipharma As Use of alginate oligomers as blood anticoagulants
MX2016008304A (es) * 2013-12-23 2017-01-09 Norwegian Univ Of Science And Tech Usos de oligouronatos en el tratamiento de cancer.
JP2017510563A (ja) * 2014-02-28 2017-04-13 アルギファルマ エーエス 嚢胞性線維症及び欠陥ｃｆｔｒイオンチャネル機能に関連する他の病態の治療におけるアルギネートオリゴマーの使用
FR3024358B1 (fr) * 2014-08-01 2017-11-10 Soc De Courtage Et De Diffusion Codif Int Compositions cosmetiques et complements alimentaires neuro-protecteurs comprenant de l'oligoalginate ayant un degre de polymerisation de 10 pour lutter contre le vieillissement de la peau.
GB201415381D0 (en) * 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
GB201504878D0 (en) * 2015-03-23 2015-05-06 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
GB201517639D0 (en) 2015-10-06 2015-11-18 Algipharma As Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
US12649000B2 (en) 2018-03-19 2026-06-09 Algipharma As Use of alginate oligomers to enhance the translocation of micro/nanoparticles across mucus layers
GB201812473D0 (en) 2018-07-31 2018-09-12 Algipharma As Method for the qualitative and quantitative detection of alginate oligomers in body fluids
GB201908639D0 (en) 2019-06-17 2019-07-31 Algipharma Ipr As Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense microstructure
CN115005447B (zh) * 2022-06-16 2024-02-06 青岛海关技术中心 低聚古罗糖醛酸在制备抗疲劳产品中的应用
EP4393472A1 (en) * 2022-12-27 2024-07-03 Abbas Mirshafiey Mannuronate, guluronate and gulumannuronate tablet, capsule or ampoule formulation and method for its preparation
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
CN117482279A (zh) * 2023-06-20 2024-02-02 湖南易天然医疗科技有限公司 一种雾化液体敷料及其制备方法
WO2026008878A1 (en) 2024-07-04 2026-01-08 Algipharma As Antimycotic polyene-alginate oligomer conjugates
GB202418172D0 (en) 2024-12-11 2025-01-22 Algipharma As Compositions and methods

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297511A (da) 1956-12-20
FR7576M (da) * 1968-03-27 1970-01-05
HU172831B (hu) * 1976-03-31 1978-12-28 Egyt Gyogyszervegyeszeti Gyar Sposob poluchenija kompleksov oligo- i poligalakturonnyk kislot s ionami zhiznenno vazhnykh metallov
JPS6176413A (ja) 1984-09-21 1986-04-18 Junzo Sunamoto 吸水性高分子によりカプセル化されたリポソ−ムの製造法
DD268865A1 (de) * 1987-01-16 1989-06-14 Adw Ddr Verfahren zur herstellung eines pharmazeutischen praeparates
US4898852A (en) * 1987-06-02 1990-02-06 Walsh William E Cyclopolgalcturonic acid composition and treatment
US4855128A (en) * 1988-01-14 1989-08-08 Warner-Lambert Company Saccharide inhibition of dental plaque
JP2641472B2 (ja) 1988-01-30 1997-08-13 日本レダリー株式会社 感染症治療剤
EP0502949A4 (en) 1989-12-05 1993-02-24 Trancel Corporation Homologous guluronic acid alginate coating composition for in-vivo application and implantation and method of using same
US5459054A (en) 1989-12-05 1995-10-17 Neocrin Company Cells encapsulated in alginate containing a high content of a- l- guluronic acid
WO1991011205A1 (en) 1990-01-23 1991-08-08 Trancel Corporation Mannuronic acid containing alginate wound healing composition and method
US5166137A (en) * 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
US5952308A (en) * 1991-07-29 1999-09-14 Pola Chemical Industries Inc. Mineral absorption promoting agent
US5460957A (en) 1992-04-28 1995-10-24 Maruha Corporation Calcium alginate oligosaccharide and method for producing the same from potassium or sodium alginate
HU213872B (en) 1993-09-08 1997-11-28 Mta Koezponti Kemiai Kutato In Oligo- and polygalacturonate mixed complex, pharmaceutical and food compositions containing them, further process for preparing these compounds
DE4330773A1 (de) * 1993-09-10 1995-03-16 Laevosan Gmbh & Co Kg Blockierung der Anlagerung von Keimen an menschliche Zellen
JP2828391B2 (ja) 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
JP4421681B2 (ja) * 1995-10-19 2010-02-24 バイオ‐オリジン エルエルシー 生殖細胞および胚の生存および機能を改善する方法および組成物
JP3512553B2 (ja) * 1996-01-30 2004-03-29 ポーラ化成工業株式会社 便秘抑制剤及びそれを含有する組成物
FR2747045B1 (fr) * 1996-04-05 1998-06-26 Hooreman Michel Nouveau medicament optimisant la viscosite des mucus et ameliorant le fonctionnement de l'intestin
NO305441B1 (no) 1996-07-12 1999-05-31 Norsk Hydro As Anvendelse av G-blokk polysakkarider
DE69732308T2 (de) 1996-09-27 2005-06-02 Jagotec Ag Arzneistoffverabreichungssystem mit hyaluronsäure
NO305033B1 (no) 1997-05-09 1999-03-22 Algipharma As Fremgangsmate for fremstilling av uronsyreblokker fra alginat
US6339075B1 (en) 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
KR100219918B1 (ko) 1997-07-03 1999-09-01 김윤 대장선택적 약물전달용 조성물
JP3932679B2 (ja) 1998-07-21 2007-06-20 セイコーエプソン株式会社 ポリグルロン酸の製造法
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
WO2001015672A2 (en) * 1999-08-26 2001-03-08 Governors Of The University Of Alberta Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
US20040224922A1 (en) * 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7785625B2 (en) 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
KR100501584B1 (ko) * 2000-02-03 2005-07-18 (주)케이비피 저분자 폴리만유로네이트의 제조방법, 혈청지질개선제로서의 이의 신규 용도 및 이를 함유하는 기능성식품 및 건강 보조 식품
DE10006989A1 (de) * 2000-02-16 2001-08-23 Nutricia Nv Antiadhäsive Kohlenhydratmischung
AU2001243431B2 (en) 2000-03-07 2006-05-25 Rush University Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
AU4445201A (en) 2000-03-30 2001-10-08 Generex Pharmaceuticals Inc. Method for administering insulin to the buccal region
DE10019076A1 (de) * 2000-04-06 2001-10-18 Lang Christine Verwendung von Polygalakturoniden als Lebensmittelzusatzstoffe
JP2002338493A (ja) 2000-10-23 2002-11-27 Genaera Corp ムチン合成インヒビター
DE10057976B4 (de) 2000-11-22 2005-02-03 Südzucker AG Mannheim/Ochsenfurt Verfahren zur Herstellung von Pektinhydrolyseprodukten
US6440314B1 (en) * 2001-01-03 2002-08-27 Vulcan Chemical Technologies, Inc. Method for destroying chlorite in solution
ITMI20010347A1 (it) 2001-02-21 2002-08-21 Grisotech S A Complessi di immunoglobuline e polisaccaridi per assorbimento orale etrans-mucosale
US6610331B1 (en) 2002-05-30 2003-08-26 Scott M. Sweazy Fertility kit
JP2005145885A (ja) 2003-11-14 2005-06-09 Japan Science & Technology Agency アルギン酸オリゴマーからなる免疫機構賦活剤
EP2106790B1 (en) 2004-03-12 2012-10-24 Biodel, Inc. Rapid acting drug delivery compositions
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
JP2006028041A (ja) 2004-07-13 2006-02-02 Ltt Bio-Pharma Co Ltd 核酸含有ナノ粒子
EP1714660A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
US7621036B2 (en) 2005-06-21 2009-11-24 Cardiomems, Inc. Method of manufacturing implantable wireless sensor for in vivo pressure measurement
EP1745705A1 (en) 2005-07-20 2007-01-24 N.V. Nutricia Process for preparing uronic acid oligosaccharides by extrusion
GB2430881B (en) 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
EP1940427A4 (en) 2005-10-21 2013-01-02 Living Cell Products Pty Ltd encapsulation
GB0707096D0 (en) 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
US20110130444A1 (en) 2007-05-04 2011-06-02 Stefan Moisyadi Methods and compositions for targeted delivery of gene therapeutic vectors
CA2724408A1 (en) 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids

Also Published As

Publication number Publication date
HK1125855A1 (en) 2009-08-21
ES2390974T3 (es) 2012-11-20
US20090010914A1 (en) 2009-01-08
EP3403657A1 (en) 2018-11-21
EP1942938A1 (en) 2008-07-16
WO2007039760A2 (en) 2007-04-12
AU2006298544B2 (en) 2012-07-05
BRPI0616982A2 (pt) 2011-07-05
GB2430881A (en) 2007-04-11
CN101325973B (zh) 2013-02-13
EP1954315A2 (en) 2008-08-13
EA200801033A1 (ru) 2008-10-30
ES2688971T3 (es) 2018-11-07
WO2007039754A1 (en) 2007-04-12
DK1942938T3 (da) 2012-09-17
CA2624568C (en) 2014-04-08
AU2006298544A1 (en) 2007-04-12
EP2311497B1 (en) 2018-07-11
CN101325973A (zh) 2008-12-17
ES2907875T3 (es) 2022-04-26
BRPI0616982B1 (pt) 2020-05-05
KR101144576B1 (ko) 2012-05-09
EA015436B1 (ru) 2011-08-30
EP2311497A1 (en) 2011-04-20
PL3403657T3 (pl) 2022-03-21
EP3403657B1 (en) 2021-12-08
DK2311497T3 (da) 2018-10-22
WO2007039760A3 (en) 2007-08-09
BRPI0616982B8 (pt) 2021-05-25
US20090156549A1 (en) 2009-06-18
KR20080080491A (ko) 2008-09-04
US8754063B2 (en) 2014-06-17
GB0520375D0 (en) 2005-11-16
US8673878B2 (en) 2014-03-18
JP2009511455A (ja) 2009-03-19
EP1942938B1 (en) 2012-07-04
CA2624568A1 (en) 2007-04-12
GB2430881B (en) 2010-10-13
JP5313677B2 (ja) 2013-10-09

Similar Documents

Publication Publication Date Title
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
ATE525088T1 (de) Kombinationstherapie
DE602006016980D1 (de) Stellungsverfahren dafür
NO20070251A (no) Brønnbehandling
NO20070297A (no) Brønnbehandling
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK3567035T3 (da) N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
PL1746999T3 (pl) 4-fenyloaminochinazolin-6-yloamidy
DK2781593T3 (da) Fremgangsmåde til behandling af methanemissioner
DE602005012636D1 (de) Erung
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DE602006020744D1 (de) Fertigspritze
DE602006015776D1 (de) Jet-lotbad
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
DK1709082T3 (da) Sammensætning til behandling af patologi knyttet til MSRV/HERV-W
DK1814555T3 (da) S-mirtazapin til behandling af hedeture
DK2001499T3 (da) Anvendelse af TGS-6 til behandling af osteoporose
SE0400476L (sv) Komponent
DE502006005207D1 (de) Bauteilen